<DOC>
	<DOCNO>NCT01535937</DOCNO>
	<brief_summary>This project evaluate effect single sub-anesthetic dose ketamine time first cocaine use abstinence rate 60 treatment-seeking cocaine-dependent individual receive mindfulness-based relapse prevention ( MBRP ) therapy , use 5 week combine laboratory-inpatient outpatient double-blind , randomize , control trial .</brief_summary>
	<brief_title>The Effect Brief Potent Glutamatergic Modulation Cocaine Dependence</brief_title>
	<detailed_description>study begin inpatient phase ( phase 1 ) 5 day , abstinence achieve , follow 4 week outpatient phase ( phase 2 ) . A single infusion ketamine midazolam occur day 3 Phase 1 . In addition measure mindfulness impulsivity , stress sensitivity test incorporate design order elucidate mechanism action . The study hypotheses : 1. ketamine MBRP significantly increase time first use compare placebo MBRP cocaine-dependent individual . 2. ketamine MBRP significantly likely lead abstinence cocaine ( use one week ) compare placebo MBRP . 3. ketamine MBRP significantly reduce subjective , endocrine , physiological response stress ( include cue exposure ) compare placebo MBRP . 4. ketamine MBRP significantly increase mindfulness , assess Five Facet Mindfulness Questionnaire ( FFMQ ) , compare placebo MBRP .</detailed_description>
	<mesh_term>Cocaine-Related Disorders</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Active cocaine dependence least 8 day use least 4 binge large amount ( &gt; $ 200/occasion ) past 30 day , display least one positive utox screen Physically healthy No adverse reaction study medication 2160 year age Capacity consent comply study procedure , include sufficient proficiency English Seeking treatment Meets DSM IV criterion current major depression , bipolar disorder , schizophrenia , psychotic illness , include substance induce psychosis , current substanceinduced mood disorder HAMD score &gt; 12 . Physiological dependence another substance require medical management , alcohol , opioids , benzodiazepine , exclude caffeine , nicotine , cannabis Delirium , Dementia , Amnesia , Cognitive Disorders , Dissociative disorder Current suicide risk history suicide attempt within past year Pregnant interest become pregnant study period Heart disease indicate history , abnormal ECG , previous cardiac surgery . Unstable physical disorder might make participation hazardous endstage AIDS , hypertension ( &gt; 140/90 ) , WBC &lt; 3.5 , active hepatitis liver disease elevate transaminase level ( &lt; 23 X upper limit normal consider acceptable PT/PTT normal ) , renal failure ( creatinine &gt; 2 , BUN &gt; 40 ) , untreated diabetes Previous history ketamine benzodiazepine misuse abuse , history adverse reaction/experience prior exposure ketamine benzodiazepine Recent history significant violence ( past 2 year ) First degree relative psychotic disorder ( bipolar disorder , schizophrenia , schizoaffective disorder , psychosis NOS ) BMI &gt; 32 , history document obstructive sleep apnea On psychotropic medication whose effect could disrupt participation study Patients comply study procedures initial hospitalization phase</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>